MetaVia MTVA
NASDAQ MTVA
$1.54 +0.00 (+0.00%)
At close: Oct 2, 2026 · 4:00 PM EDT

MetaVia (MTVA) Gains from Sales and Divestitures (2022)

Updated

MetaVia's Gains from Sales and Divestitures came in at -$75,000 for FY2022.

Analysis

MetaVia (MTVA) Gains from Sales and Divestitures (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 MetaVia 10.13 Mn -44.69 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2022 -75,000.00
API Access

MetaVia Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=MTVA&period=max&api_key=YOUR_API_KEY